Arvinas Announces Changes to its Board of Directors : compar

NEW HAVEN, Conn., June 15, 2023 -- Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Timothy Shannon,... | June 15, 2023

Related Keywords

Washington , United States , John Houston , Sunil Agarwal , Jeff Boyle , Timothy Shannon , Briggs Morrison , Head Of Development , Genentech , Sana Biotechnology Inc , Cornell University , Arvinas Inc , Global Head Of Clinical Development , Nasdaq , Exchange Commission , Children National Medical Center , Tufts University School Of Medicine , Pediatric Emergency Department , Lead Independent Director , Arvina Board , Chief Executive Officer , Executive Vice President , Chief Medical Officer , Sana Biotechnology , Ultragenyx Pharmaceutical , Senior Vice President , Global Head , Clinical Development , National Medical Center , Tufts University School , Discovery Engine , Private Securities Litigation Reform Act , Annual Report , Arvinas , Nc Stock Exchange , News , Information , Press Release , Few , Pune , 023 , Biotechnology , Company , Reating , Glass , F , Drugs , Ased , N , Argeted , Protein , Oday , Nnounced , Hat , Imothy Arvn Us04335a1051 ,